ESC 365 - Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

ESC Premium Access

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

Session: Poster Session 2 - Drug treatment for atrial fibrillation

Topic: Oral Anticoagulation

Speaker: Doctor G. Montrasio (London, GB)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Giulia Montrasio

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

0 follower

9 more presentations in this session

Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

Speaker: Doctor W. Amara (Le Raincy-Montfermeil, FR)

Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation

Speaker: Doctor M. Mihajlovic (Belgrade, RS)

Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging

Speaker: Associate Professor M. Harada (Toyoake, JP)

Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples

Speaker: Doctor O. Hajas (Debrecen, HU)

Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials

Speaker: Professor H. Crijns (Maastricht, NL)

Access the full session

Poster Session 2 - Drug treatment for atrial fibrillation

Speakers: Doctor G. Montrasio, Doctor W. Amara, Doctor M. Mihajlovic, Associate Professor M. Harada, Doctor O. Hajas...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources